CEO/executive purchases are positive but the dollar amount is trivial relative to Elanco's market cap. The buys align with the 91% bullish analyst consensus but do not signal material new information. Monitor for larger insider accumulation or the next 8-K earnings release for substantive catalysts.
ELAN drugs
ELAN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 27 $23.61entry
- T+1 · 6mo ago +1.48%α +0.93% · $23.96
- T+5 · 6mo ago +4.11%α +3.64% · $24.58
- T+20 · 5mo ago +1.49%α +3.79% · $23.96
- T+60 · 3mo ago −0.21%α −1.83% · $23.56
Price Chart
How similar events traded
Executive Summary
Elanco's CEO Jeffrey Simmons and another senior executive made open-market purchases totaling $200K on May 15. In addition, eight directors received non-cash stock grants of 4,678 shares each on May 21, a routine director compensation event with no economic outlay. The CEO/executive buys are the sole cash transactions and represent ~0.002% of Elanco's $10.9B market cap, a trivial amount with no material signal. With a 91% analyst buy rating, the insider purchases appear consistent with existing bull sentiment rather than new information.
Key Financial Metrics
Key Facts
- CEO Jeffrey Simmons purchased 5,000 shares for ~$100K on May 15
- Executive Modi Rajeev purchased 4,900 shares for ~$100K on May 15
- Total open-market purchases: $200K vs $10.9B market cap = ~0.002%
- Eight directors received identical non-cash grants of 4,678 shares each on May 21 (total $0 cash)
Financial Impact
Two open-market buys totaling $200K, representing ~0.002% of $10.9B market cap, de minimis. Director grants are non-cash compensation with zero economic value.
Risk Factors
- The $200K total purchase is 0.002% of market cap, statistically noise; overstated reaction risk
- Director grants are routine compensation, not conviction buys
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ELAN-1779828423521 |
Track record
19 reports on ELAN
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
- Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
- Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
- Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
- Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers